ライフサイエンスコーパス: Hurthle cell

1 (24 papillary, 11 malignant FNA, 5 oncocytic/Hurthle cell, 2 medullary, 1 follicular, and 4 metastase

2 However, delineation between Hurthle cell adenoma versus carcinoma often cannot relia

3 = 18), and histopathologically well-defined Hurthle cell adenomas (n = 27), Hurthle cell tumors of u

4 n tumors (four follicular adenomas and three Hurthle cell adenomas) and only 3 of 49 (6.1%) informati

5 carcinomas and reserve thyroid lobectomy for Hurthle cell adenomas.

6 follicular thyroid adenomas and 1 of 9 (11%) Hurthle cell adenomas.

7 nfunctioning follicular adenomas, and 9 were Hurthle cell adenomas.

8 id carcinoma (125 papillary, 2 follicular, 8 Hurthle cell, and 13 poorly differentiated) approximatel

9 rrent and metastatic cancer in patients with Hurthle cell cancer but also opens up an alternative the

10 showed intense (18)F-FDG uptake in all known Hurthle cell cancer lesions but one.

11 ch was not a previously described marker for Hurthle cell cancer of the thyroid, was demonstrated by

12 Patients with Hurthle cell cancer who were seen between June 2000 and

13 papillary cancers, 10 follicular cancers, 1 Hurthle cell cancer, 1 medullary cancer, and 1 carcinosa

14 utility of PET in a series of patients with Hurthle cell cancer.

15 lusively includes patients with papillary or Hurthle cell cancers.

16 ciated with the diagnosis of widely invasive Hurthle cell carcinoma (P < 0.001).

17 conduct a critical histopathologic review of Hurthle cell carcinoma and to correlate morphologic para

18 Hurthle cell carcinoma demonstrates intense uptake on (1

19 Patients with Hurthle cell carcinoma have a prognosis that is predicte

20 ions exist for follicular thyroid cancer and Hurthle cell carcinoma in evidence-based guidelines.

21 Hurthle cell carcinoma is an uncommon and occasionally a

22 Hurthle cell carcinoma is an uncommon differentiated thy

23 tion and disease management in patients with Hurthle cell carcinoma relative to anatomic or iodine im

24 h (18)F-FDG PET in the care of patients with Hurthle cell carcinoma to determine the likelihood of up

25 s predict a worse outcome in widely invasive Hurthle cell carcinoma, as does extrathyroidal extension

26 ion and clinical management of patients with Hurthle cell carcinoma.

27 All patients had documented Hurthle cell carcinoma.

28 rphology to predict the biologic behavior of Hurthle cell carcinoma.

29 d surgeons recommend total thyroidectomy for Hurthle cell carcinomas and reserve thyroid lobectomy fo

30 in the clinically aggressive widely invasive Hurthle cell carcinomas and was associated with signific

31 However, patients with Hurthle cell carcinomas had significantly larger tumors

32 in FTCs, including insular type tumors, and Hurthle cell carcinomas in comparison with normal thyroi

33 imally (n = 14) and widely (n = 21) invasive Hurthle cell carcinomas were arrayed in triplicate on ti

34 inomas, 0 of 40 follicular adenomas, 1 of 30 Hurthle cell carcinomas, 1 of 90 papillary carcinomas, a

35 inomas, 9 were anaplastic carcinomas, 5 were Hurthle cell carcinomas, 21 were nonfunctioning follicul

36 but also in papillary thyroid carcinomas and Hurthle cell carcinomas.

37 may be useful for diagnosing widely invasive Hurthle cell carcinomas.

38 licular neoplasm (n = 14), and suspicion for Hurthle cell neoplasm (n = 5) were enrolled in the study

39 These data demonstrate that the size of a Hurthle cell neoplasm is predictive of malignancy.

40 for follicular neoplasm," or "suspicion for Hurthle cell neoplasm," were enrolled after obtaining in

41 ents, frozen section showed a "follicular or Hurthle cell neoplasm." Permanent histology demonstrated

42 at the time of initial exploration for large Hurthle cell neoplasms (>4 cm), definitive resection inv

43 atients who underwent thyroid resections for Hurthle cell neoplasms between October 1984 and April 19

44 Of the 57 patients with Hurthle cell neoplasms, 37 had adenomas and 20 had carci

45 index was associated with adverse outcome in Hurthle cell neoplasms.

46 yet to be identified, whereas that for some Hurthle cells (TCO) has been mapped to chromosome 19p13.

47 FDG PET has excellent diagnostic accuracy in Hurthle cell thyroid cancer patients, improving on CT an

48 Our data suggest that all patients with Hurthle cell thyroid cancer should undergo 18F-FDG PET a

49 All patients with Hurthle cell thyroid cancer who underwent their first 18

50 lterations in the p53 pathway play a role in Hurthle cell tumorigenesis, but other unidentified molec

51 haracterize molecular expression profiles of Hurthle cell tumors and to determine the clinical signif

52 Hurthle cell tumors are rare thyroid neoplasms for which

53 well-defined Hurthle cell adenomas (n = 27), Hurthle cell tumors of unknown malignant behavior (n = 7

54 The molecular phenotype of Hurthle cell tumors, independent of histopathological su

55 pillary cancers, 7 follicular cancers, and 4 Hurthle cell tumors.